Lodestone Biomedical

Lodestone Biomedical is a private, pre-revenue diagnostics company spun out of Dartmouth College in 2020, headquartered in Lebanon, New Hampshire. The company is developing a proprietary biosensing platform designed to detect and monitor immune responses within the tumor microenvironment in real-time, providing a novel tool for preclinical cancer research and drug development. Led by a team with deep expertise in biomedical device R&D, Lodestone aims to address a critical bottleneck in oncology research by enabling faster, more confident decision-making in early-stage compound screening. Its technology represents a platform approach to understanding disease processes at a cellular level, with the potential to significantly accelerate the discovery of new cancer treatments.

Immune Response Indication System (IRIS) - a biosensing platform using magnetic detection methods to monitor real-time immune responses within the tumor microenvironment in preclinical research models.

Lodestone competes in the broad market for preclinical oncology research tools, which includes established players offering genomic, proteomic, and imaging solutions. Its differentiation hinges on real-time, cellular-level immune monitoring within the tumor microenvironment, a niche not fully addressed by standard endpoint assays or bulk analysis techniques.